pharmaphorum2d
The rise and market race of anti-IL23p19 therapies in IBD: How ECCO 2025 readouts will shape the anti-interleukin landscape
The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...
BMJ24d
Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
z5.keio.jp Objectives To investigate the possible role of baseline plasma tumour necrosis factor alpha levels (baseline-TNF) on the clinical response to infliximab in patients with rheumatoid ...
gut.bmj18d
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
The mechanism of resistance to anti-tumour necrosis factor α (anti-TNFα ... synthase 2 (PTGS2), interleukin 13 receptor alpha 2 (IL13Ralpha2) and interleukin 11 (IL11), and predicted the response to ...
BMJ26d
Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis
Recently biological blockade with the tumour necrosis factor alpha (TNFα) antagonists infliximab and etanercept has been shown to be effective in the treatment of SpA. However, only infliximab is ...
gut.bmj17d
Early Crohn disease: a proposed definition for use in disease-modification trials
including tumour necrosis factor-alpha (TNF-α) inhibition with infliximab, adalimumab or certolizumab pegol, and chemokine receptor CCR9 inhibition with CCX282-B.14 Safety is an important concern when ...
The American Journal of Managed Care2d
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Originator in IBD
Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...
Medscape1d
Anti-TNF-α Agents in the Treatment of Immune-mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls
TNF-α is a potent inductor of the inflammatory response, a key cytokine in the development of the innate immune response. Soluble TNF-α acts on many hematopoietic and nonhematopoietic cell types ...
Why anti-TNF drugs don't work for some kids with Crohn's disease
A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...
Medscape26d
Tumor Necrosis Factor Alpha Inhibitors for the Treatment of Dermatologic Diseases
Tumor necrosis factor alpha (TNF α) is involved in cell differentiation, mitogenesis, cytotoxic responses, inflammation, immunomodulation, and wound healing. Because of its numerous roles ...